Biopharmaceutical Approvals in the US and EU: A Review
BioPharm International-10-01-2010
Venture capital is still scarce for early biotechs and their providers.
Can vendor-user partnerships overcome the typical wait-and-see attitude toward new technologies?
Biotech approvals were up last year. Is it a sign of a new trend?
How should the industry educate the public about product quality?
A new strategy to streamline vaccine development and oversight.
Good leaders look beyond industry woes to focus on patients
Biotech's mid-sized elites position themselves for growth.
Industry and regulators disagree over noncritical parameters.
Advertisement
Advertisement